New lymphoma drug trial halted early after testing in 18 patients

NCT ID NCT04903197

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage trial tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin Lymphoma that had come back or not responded to prior treatments. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Shanghai, 200032, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Leipzig, 04103, Germany

  • Novartis Investigative Site

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Yamagata, Yamagata, 990 9585, Japan

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea